Back

Finerenone vs spironolactone: comparative effectiveness and safety in patients with HFpEF and chronic kidney disease

30 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Exploring the peripheries in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jacob Hicks

Emory Healthcare, Atlanta (United States of America)

6 More presentations in this session

Presentation thumbnail
Non-invasive pulse-wave-analysis for screening of HFpEF in at-risk patients: findings from the ARTS-PREDICTION study
Doctor J. Gronwald (Goettingen, DE)
Abstract
Presentation thumbnail
Finerenone versus spironolactone in HFpEF patients with type 2 diabetes and CKD: a real-world comparative analysis
Doctor T. Elimihele (Iowa City, US)
Abstract
Presentation thumbnail
Incremental risk stratification using the H2FPEF score in patients with chronic kidney disease and unexplained dyspnea
Mr A. Al-Rubai (Copenhagen, DK)
Abstract
Presentation thumbnail
Prevalence and reclassification of monoclonal gammopathy in elderly HFpEF patients undergoing ATTR-CM screening: A PATCH-HFpEF sub-study
Doctor P. Liao (TW)
Abstract
Presentation thumbnail
Diagnostic performance of the H₂FPEF score and cardiovascular burden in patients with chronic kidney disease: a cross-sectional study
Doctor M. Covic (Iasi, RO)
Abstract

Access the full session

Session thumbnail
Exploring the peripheries in HFpEF

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Session
Improving patient outcomes in heart failure: the role of finerenone
19 May 2025
thumbnail
Congress Presentation
The impact of advanced chronic kidney disease on therapeutic management of chronic heart failure with reduced ejection fraction
20 May 2023
thumbnail
ESC Journals
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial
20 November 2020
thumbnail
Congress Presentation
Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study
21 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources